Stocks and Investing
Stocks and Investing
Thu, March 28, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matt O"Brien Initiated (TMDX) at Buy and Held Target at $95 on, Mar 28th, 2024
Matt O"Brien of Piper Sandler, Initiated "TransMedics Group, Inc." (TMDX) at Buy and Held Target at $95 on, Mar 28th, 2024.
Matt has made no other calls on TMDX in the last 4 months.
There are 3 other peers that have a rating on TMDX. Out of the 3 peers that are also analyzing TMDX, 1 agrees with Matt"s Rating of Hold. Following is the relevant analyst calls for the last 4 months;
Cecilia Furlong of "Morgan Stanley" Maintained at Hold with Increased Target to $95 on, Wednesday, February 28th, 2024
These are the ratings of the 2 analyists that currently disagree with Matt;
Suraj Kalia of "Oppenheimer" Maintained at Buy with Increased Target to $105 on, Tuesday, February 27th, 2024 Allen Gong of "JP Morgan" Maintained at Buy with Increased Target to $105 on, Tuesday, February 27th, 2024
Contributing Sources